Entecavir: A new nucleoside analogue for the treatment of chronic hepatitis B

Drugs of Today

Volumn 43, Issue 4, 2007, Pages 201-220

  Rivkin, Anastasia ^a,b  

^a LONG ISLAND UNIVERSITY   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACICLOVIR; ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; DIDANOSINE; ENTECAVIR; GANCICLOVIR; LAMIVUDINE; LOBUCAVIR; MYCOPHENOLIC ACID; PEGINTERFERON ALPHA2A; PENCICLOVIR; PLACEBO; RIBAVIRIN; STAVUDINE; TELBIVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE;

ABDOMINAL PAIN; AGE DISTRIBUTION; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; CHRONIC DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; ANTIBIOTIC RESISTANCE; DRUG INTERACTION; FIBROSIS;

ANIMALS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; FIBROSIS; GUANINE; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 34447316464     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2007.43.4.1037479     Document Type: Review

References (107)

1. Lee, W.M. Hepatitis B virus infection. N Engl J Med 1997, 337: 1733-45.
2. Fact sheet N204, 2000, World Health Organization. Available at http://www.who.int/mediacentre/factsheets/fs204/en/.
3. Lai, C.L., Ratziu, V., Yuen, M.F. et al. Viral hepatitis B. Lancet 2003, 362: 2089-94.
4. Lok, A.S. Chronic hepatitis B. N Engl J Med 2002, 346: 1682-3.
5. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11: 97-107.
6. Disease Burden from Hepatitis A, B, and C in the United States. Centers for Disease Control and Prevention 2005. Available at http: //www.cdc.gov/ncidod/diseases/hepatitis/resource/dzj_Durden02.htm.
7. State and County Quickfacts: 01 February 2005. U.S. Census Bureau. Available at http://quickfacts.census.gov/qfd/states/00000.html.
8. Guane, R., Siu, O., Lam, K. et al. Prevalence of HBV acquisition in hepatitis B screening programs in large metropolitan cities in the United States. Hepatology 2004, 40 (Suppl.): 716A.
9. Sherman, M., Tsang, T., Villaneuva, G. et al. Mass screening in New York City reveal extraordinary high prevalence of hepattiis B in an urban Asian population. Hepatology 2005, 42 (Suppl.): 214A.
10. McMahon, B.J. Selecting appropriate management strategies for chronic hepatitis B: Who to treat. Am J Gastroenterol 2006, 101 (Suppl. 1): S7-12.
11. Fattovich, G., Brollo, L., Giustina, G. et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991, 32: 294-8.
12. Fattovich, G., Giustina, G., Schalm, S.W. et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995, 21: 77-82.
13. Lok, A.S., McMahon, B.J. Chronic hepatitis B: Update of recommendations. Hepatology 2004, 39: 857-61.
14. Lok, A.S., Heathcote, E.J., Hoofnagle, J.H. Management of hepatitis B: 2000 - Summary of a workshop. Gastroenterology 2001, 120: 1828-53.
15. McMahon, B.J., Hoick, P., Bulkow, L. et al. Serologic and clinical outcomes of 1,536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135: 759-68.
16. Adachi, H., Kaneko, S., Matsushita, E. et al. Clearance of HBsAg in seven patients with chronic hepatitis B. Hepatology 1992, 16: 1334-7.
17. Liaw, Y.F., Sheen, I.S., Chen, T.J. et al. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: A prospective study. Hepatology 1991, 13: 627-31.
18. Keeffe, E.B., Dieterich, D.T., Han, S.H. et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update. Clin Gastroenterol Hepatol 2006, 4: 936-62.
19. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention. MMWR 2001, 50(RR-11): 1-42.
20. Wright, T.L. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006, 101 (Suppl. 1): S1-6.
21. Sherman, M. Personal view: The management of chronic hepatitis B infection. Aliment Pharmacol Ther 2006, 23: 857-69.
22. Chen, C.J., Yang, H.I., Su, J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295: 65-73.
23. Iloeje, U.H., Yang, H.I., Su, J. et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130: 678-86.
24. Wong, D.K., Cheung, A.M., O'Rourke, K. et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119: 312-23.
25. Lin, S.M., Sheen, I.S., Chien, R.N. et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999, 29: 971-5.
26. Lau, D.T., Everhart, J., Kleiner, D.E. et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997, 113: 1660-7.
27. Lok, A.S., Chung, H.T., Liu, V.W. et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993, 105: 1833-8.
28. Krogsgaard, K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 1998, 5: 389-97.
29. Lau, G.K., Piratvisuth, T., Luo, K.X. et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005, 352: 2682-95.
30. Dienstag, J.L, Schiff, E.R., Wright, T.L et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341: 1256-63.
31. Lai, C.L., Chien, R.N., Leung, N.W. et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998, 339: 61-8.
32. Schalm, S.W., Heathcote, J., Cianciara, J. et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000, 46: 562-8.
33. Dienstag, J.L., Cianciara, J., Karayalcin, S. et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003, 37: 748-55.
34. Song, B.C., Suh, D.J., Lee, H.C. et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000, 32: 803-6.
35. Lee, K.M., Cho, S.W., Kim, S.W. et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002, 9: 208-12.
36. Marcellin, P., Chang, T.T., Lim, S.G. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003, 348: 808-16.
37. Marcellin, P., Chang, T.T., Lim, S.G. et al. Long term efficacy and safety of adefovir dipivoxil (ADV) 10mg in the HBeAg+ chronic hepatitis B (CHB) patients: Increasing serologic, virologic and biochemical response over time. Hepatology 2004, 40 (Suppl.): 655A.
38. Locarnini, S., Qi, X., Arterburn, S. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). 40th Annual Meeting of the European Association for the Study of the Liver, Paris 2005, Abst. 36.
39. Chang, T.T., Gish, R.G., de Man, R. et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354: 1001-10.
40. Keeffe, E.B., Dieterich, D.T., Han, S.H. et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004, 2: 87-106.
41. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. J Hepatol 2003, 39 (Suppl. 1): S1-235.
42. Liaw, Y.F., Leung, N., Guan, R. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: An update. J Gastroenterol Hepatol 2003, 18: 239-45.
43. Liaw, Y.F., Leung, N., Guan, R. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005, 25: 472-89.
44. Chu, C.J., Hussain, M., Lok, A.S. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002, 36: 1408-15.
45. Shaw, T., Locarnini, S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004, 2: 853-71.
46. Schneller, S.W. Carbocyclic nucleosides (carbanucleosides) as new therapeutic leads. Curr Top Med Chem 2002, 2: 1087-92.
47. Seifer, M., Hamatake, R.K., Colonno, R.J. et al. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998, 42: 3200-8.
48. Yamanaka, G., Wilson, T., Innaimo, S. et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999, 43: 190-3.
49. Baraclude™ (entecavir) package insert. Bristol Myers Squibb Company. Princeton, NJ, March 2005.
50. Bifano, M., Yan, J., Xie, J. et al. Hepatic impairment does not alter single-dose pharmacokinetics and safety of entecavir. Hepatology 2004, 40 (Suppl.): 663A.
51. Wolters, L.M., Hansen, B.E., Niesters, H.G. et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002, 37: 137-44.
52. Innaimo, S.F., Seifer, M., Bisacchi, G.S. et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997, 41: 1444-8.
53. Ruediger, E., Martel, A., Manwel, N. et al. Novel 3′-deoxy analogs of the anti-HBV agent entecavir: Synthesis of enantiomers from a single chiral epoxide. Tetrahedron Lett 2004, 45: 739-42.
54. Levine, S., Hernandez, D., Yamanaka, G. et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002, 46: 2525-32.
55. Zoulim, F. Entecavir: A new treatment option for chronic hepatitis B. J Clin Virol 2006, 36: 8-12.
56. Colonno, R.J., Genovesi, E.V., Medina, I. et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001, 184: 1236-45.
57. Genovesi, E.V., Lamb, L., Medina, I. et al. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998, 42: 3209-17.
58. Tuttleman, J.S., Pourcel, C., Summers, J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986, 47: 451-60.
59. Wu, T.T., Coates, L., Aldrich, C.E. et al. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990, 175: 255-61.
60. Dandri, M., Burda, M.R., Will, H. et al. Increased hepatocyte turnover and inhibitionof woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000, 32: 139-46.
61. Moraleda, G., Saputelli, J., Aldrich, C.E. et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997, 71: 9392-9.
62. Marion, P.L., Salazar, F.H., Winters, M.A. et al. Potent efficacy of entecavir (BMS-2004 75) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002, 46: 82-8.
63. Foster, W.K., Miller, D.S., Marion, PL. et al. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob Agents Chemother 2003. 47: 2624-35.
64. de Man, R.A., Wolters, L.M., Nevens, F. et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001, 34: 578-82.
65. Lai, C.L., Rosmawati, M., Lao, J. et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002, 123: 1831-8.
66. Chang, T.T., Chao, Y.C., Kaymakoglu, S. et al. Entecavir maintained virologic suppression through 3 years of treatment in antiviralnaive HBeAg-positive patients. Program and abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases, Boston 2006, Abst. 109.
67. Lai, C.L., Shouval, D., Lok, A.S. et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354: 1011-20.
68. Poordad, F, Dieterich, D.T., Min, A.D. Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027). Digestive Disease Week, Los Angeles 2006, Abst. A T1851.
69. Shouval, D., Akarca, U.S., Hatzis, G. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (study ETV-027). 41st Annual Meeting of the European Association for the Study of the Liver, Vienna 2006, Abst. A45.
70. Chang, T.T., Gish, R.G., Hadziyannis, S.J. et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005, 129: 1198-209.
71. Sherman, M., Yurdaydin, C., Sollano, J. et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130: 2039-49.
72. Yurdaydin, C., Sollano, J., Hadziyannis, S. Entecavir results in continued virologic and biochemical improvement and HbeAg sero-conversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026). 41st Annual Meeting of the European Association for the Study of the Liver, Vienna 2006, Abst. A80.
73. Gish, R., de Man, R.A., Pedersen, C. Sustained response off-treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside-naive, HBeAg(-t-) patients: 24-week follow-up results of phase 3 study ETV-022. 40th Annual Meeting of the European Association for the Study of the Liver, Paris 2005, Abst. 490.
74. Shouval, D., Senturk, H., Gish, R.G. et al. Entecavir (ETV) demonstrates consistent responses throughout baseline demographic subgroups for the treatment of nucleosidenaive, HBeAg+ and HBeAg- patients with chronic hepatitis B. J Hepatol 2005, 42 (Suppl. 2): 192, Abst. 529.
75. Lurie, Y., Manns, M.P., Gish, R. The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg(-+-) and HBeAg(-) patients with chronic hepatitis B. 40th Annual Meeting of the European Association for the Study of the Liver, Paris 2005, Abst. 509.
76. Shiftman, M.L., Goodman, Z., Paul, P.J. Entecavir (ETV) is associated with an improvement in liver histology and a reduction in HBV in patients with lamivudine-refractory HBeAg(+) chronic hepatits B regardless of baseline characteristics. Digestive Disease Week, Los Angeles 2006, Abst. T1845.
77. Locarnini, S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004, 24 (Suppl. 1): 3-10.
78. Roberts, J.D., Bebenek, K., Kunkel, T.A. The accuracy of reverse transcriptase from HIV-1. Science 1988, 242: 1171-3.
79. Allen, M.I., Deslauriers, M., Andrews, C.W. et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27: 1670-7.
80. Angus, P., Vaughan, R., Xiong, S. et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125: 292-7.
81. Villeneuve, J.P., Durantel, D., Durantel, S. et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003, 39: 1085-9.
82. Gish, R.G. Clinical trial results of new therapies for HBV: Implications for treatment guidelines. Semin Liver Dis 2005, 25 (Suppl. 1): 29-39.
83. Colonno, R.J., Rose, R., Levine, S.M. et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients. Hepatology 2004, 40 (Suppl.): 661A.
84. Colonno, R., Rose, R., Baldick, C.J. et al. High barrier to resistance results in no emergence of entecavir resistance in nucleosidenaive subjects during the first 2 years of therapy. 41st Annual Meeting of the European Association for the Study of the Liver, Vienna 2006, Abst. 490.
85. Tenney, D.J., Levine, S.M., Rose, R.E. et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004, 48: 3498-507.
86. Tenney, D.J., Langley, D.R., Oliver, A.J. et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase. Hepatology 2004, 40 (Suppl.): 245A.
87. Perrillo, R.P. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis 2005, 25 (Suppl. 1): 20-28.
88. Colonno, R., Rose, R.E., Levine, S. Rare entecavir resistance after long-term treatment linked to previous lamivudine resistance. 40th Annual Meeting of the European Association for the Study of the Liver, Paris 2005, Abst. 478.
89. Schiff, E., Lee, W.M., Chao, Y.C. Efficacy and safety of entecavir and lamivudine in compensated, cirrhotic patients with chronic hepatitis B: Subgroup analysis of ETV phase III trials. 56th Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco 2005, Abst. 986.
90. Shire, N.J., Sherman, K.E. Management of HBV/HIV-coinfected Patients. Semin Liver Dis 2005, 25 (Suppl. 1): 48-57.
91. Law, W.P., Duncombe, C.J., Mahanontharit, A. et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. Aids 2004, 18: 1169-77.
92. Konopnicki, D., Mocroft, A., de Wit, S. et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids 2005, 19: 593-601.
93. Thio, C.L., Seaberg, E.C., Skolasky, R. Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360: 1921-6.
94. Dimitrakopoulos, A., Takou, A., Haida, A. et al. The prevalence of hepatitis B and C in HIV-positive Greek patients: Relationship to survival of deceased AIDS patients. J Infect 2000, 40: 127-31.
95. Rodriguez-Mendez, M.L., Gonzalez-Quintela, A., Aguilera, A. et al. Association of HCV and HBV markers in Spanish HIV-seropositive patients in relation to risk practices. Hepato gastroenterology 2003, 50: 2093-7.
96. Bodsworth, N.J., Cooper, D.A., Donovan, B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991, 163: 1138-40.
97. Pessoa, W., Gazzard, B., Huang, A. et al. Entecavir in HIV/HBV-co-infected patients: Safety and efficacy in a phase II study (ETV-038). 12th Conference on Retroviruses and Opportunistic Infections, Boston 2005, Abst. 123.
98. Sollano, J., Schiff, E., Carrilho, F. et al. Entecavir is well-tolerated for treatment of chronic hepatitis B: Phase III safety analysis in nucleoside-naive and lamivudine-refractory patients. Hepatology 2004, 40 (Suppl.): 665A.
99. Rivkin, A. A review of entecavir in the treatment of chronic hepatitis B infection. Curr Med Res Opin 2005, 21: 1845-56.
100. Colonno, R.J., Discotto, L., Gong, Y.F. et al. Combination studies involving entecavir and HIV nucleoside reverse transcriptase inhibitors showed no antagonistic effects on HBV or HIV activity in vitro. J Hepatol 2004, 40 (Suppl.): 110A.
101. Ying, C., De Clerq, E., Colonno, R.J. et al. Ribavirin and mycophenolic acid potentiate the activity of entecavir against hepatitis B virus. Antivir Res 2004, 62 (Suppl.): 47A.
102. Delaney, W.E.t., Yang, H., Miller, M.D. et al. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004, 48: 3702-10.
103. Peters, M.G., Hann Hw, H., Martin, P. et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126: 91-101.
104. Sung, J., Lai, J.Y., Zeuzem, S. et al. A randomized double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment-naive patients with chronic hepatitis B (CHB): A week-52 analysis. J Hepatol 2003, 38 (Suppl.): 4313A.
105. Marcellin, P., Lau, G.K., Bonino, F. et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351: 1206-17.
106. Akarca, U.S., Ersoz, G., Gunsar, F. et al. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther 2004, 9: 325-34.
107. Janssen, H.L., van Zonneveld, M., Senturk, H. et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 2005, 365: 123-9.